Wells Fargo’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wells Fargo’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-750,000	Closed	-$75.2M	–	7382
2025 Q3	$75.2M	Buy	+750,000	New	+$67.6M	0.01%	722
2022 Q3	–	Sell	-25,000	Closed	-$1.86M	–	7481
2022 Q2	$1.86M	Sell	25,000 -15,000	-38%	-$1.13M	﹤0.01%	2859
2022 Q1	$3.6M	Buy	+40,000	New	+$3.69M	﹤0.01%	2751
2021 Q2	–	Sell	-173,700	Closed	-$23.6M	–	7529
2021 Q1	$23.6M	Buy	+173,700	New	+$26M	0.01%	1539

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Wells Fargo's XBI Position: Q1 2026 in Review

Wells Fargo reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 23% in Q1 2026, selling an estimated $102M and leaving 2,746,209 shares worth $351M. The position accounts for 0.07% of the portfolio, ranked #257.

Wells Fargo first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $435M in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Wells Fargo held 2,746,209 shares of State Street SPDR S&P Biotech ETF worth $351M as of Q1 2026.
Wells Fargo sold 820,056 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $102M.
State Street SPDR S&P Biotech ETF made up 0.07% of Wells Fargo's portfolio in Q1 2026, its #257 holding.
Wells Fargo first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's State Street SPDR S&P Biotech ETF position peaked at $435M in Q4 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.